Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.

Abstract

Cilostazol, an inhibitor of phosphodiesterase 3B, is widely used as an anti-platelet drug in diabetic patients. Recently, cilostazol has been shown to promote preadipocyte differentiation to mature adipocyte and affect glucose homeostasis; therefore, we examined the impact of cilostazol on impaired glucose metabolism in adipose tissues of diabetic db/db… (More)
DOI: 10.1016/j.ejphar.2013.03.016

Topics

Cite this paper

@article{Wada2013CilostazolAS, title={Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.}, author={Tsutomu Wada and Yasuhiro Onogi and Yukari Kimura and Tetsuro Nakano and Hiroki Fusanobori and Yoko Ishii and Masakiyo Sasahara and Hiroshi Tsuneki and Toshiyasu Sasaoka}, journal={European journal of pharmacology}, year={2013}, volume={707 1-3}, pages={120-9} }